ERN RARE LIVER: The European Reference Network in Rare Liver Disease
Articles
- Position statement on access to care in rare liver diseases: advancements of the European reference network (ERN) RARE-LIVER
- PS-194-Effects of the ileal bile acid transport inhibitor A4250 on serum bile acids, pruritus and sleep in patients with Alagille syndrome: Phase 2 study results
- FRI-060-Effects of the ileal bile acid transport inhibitor A4250 on pruritus and serum bile acids in patients with biliary atresia: phase 2 study results
- PS-193-Phase 2 open-label study with a placebo-controlled drug withdrawal period of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with Alagille Syndrome: 48-week interim efficacy analysis
- Reply to: ‘‘Splenic artery aneurysms, portal hypertension and pregnancy”
- Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study
- Porto-sinusoidal vascular disease: proposal and description of a novel entity
- Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study
- Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease
- Nonselective beta‐blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study
- Letter: nonselective beta‐blockers, endoscopic therapy and portal vein thrombosis in cirrhosis. Authors' reply
- Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari syndrome
- Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
- Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
- Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies
- Individualizing Care: Management Beyond Medical Therapy
- Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response
- The challenges of primary biliary cholangitis: What is new and what needs to be done
- A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis
- Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis
- Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
- Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma
- Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase‐A/5‐Hydroxytryptamine/5‐Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis
- Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early‐stage primary biliary cholangitis
- Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency
- Precision medicine in primary biliary cholangitis
- Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms
- Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis
- Pinealectomy or light exposure exacerbates biliary damage and liver fibrosis in cholestatic rats through decreased melatonin synthesis
- Dexamethasone Conjugation to Biodegradable Avidin-Nucleic-Acid-Nano-Assemblies Promotes Selective Liver Targeting and Improves Therapeutic Efficacy in an Autoimmune Hepatitis Murine Model
- Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma
- Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethal‐7 microRNA
- Knockout of α-calcitonin gene-related peptide attenuates cholestatic liver injury by differentially regulating cellular senescence of hepatic stellate cells and cholangiocytes
- Editorial: liver transplantation for primary biliary cholangitis–the need for timely and more effective treatments
- Better end points needed in primary sclerosing cholangitis trials
- Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis
- Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group
- Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis
- The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study
- Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival
- Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months
- Clinical management of autoimmune hepatitis
- A Review on the Update of Combined Hepatocellular Cholangiocarcinoma
- Association Between Black Race and Presentation and Liver-Related Outcomes of Patients With Autoimmune Hepatitis
- Review article: unanswered clinical and research questions in autoimmune hepatitis‐conclusions of the International Autoimmune Hepatitis Group Research Workshop
- Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial
- Genetics of polycystic liver diseases
- Symptom relief and not cyst reduction determines treatment success in aspiration sclerotherapy of hepatic cysts
- Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis
- Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience
- Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
- Estrogen‐Containing Oral Contraceptives Are Associated With Polycystic Liver Disease Severity in Premenopausal Patients
- Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry
- Drug holiday in patients with polycystic liver disease treated with somatostatin analogues
- Increased Mortality Among Patients With vs Without Cirrhosis and Autoimmune Hepatitis
- Adverse events related to low dose corticosteroids in autoimmune hepatitis
- Novel insights into the assessment of risk of upper gastrointestinal bleeding in decompensated cirrhotic children
- Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation
- Human Hepatocytes and Differentiated Adult-Derived Human Liver Stem/Progenitor Cells Display In Vitro Immunosuppressive Properties Mediated, at Least in Part, through the Nonclassical HLA Class I Molecule HLA-G
- Home-based color card screening for biliary atresia: the first steps for implementation of a nationwide newborn screening in Germany
- Translational Research in Biliary Atresia: News from Mice and Men
- Fatal type B lactic acidosis in a patient with end-stage liver disease related to homozygous sickle cell disease
- Evaluation of dietary treatment and amino acid supplementation in organic acidurias and urea‐cycle disorders: On the basis of information from a European multicenter registry
- Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management
- Porto-sinusoidal vascular disease. Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver
- Drug induced liver injury and vascular liver disease
- Congenital portosystemic shunts: Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver
- Depression in patients with autoimmune hepatitis: the need for detailed psychiatric assessment
- Portal cavernoma or chronic non cirrhotic extrahepatic portal vein obstruction
- Social and medical support initiatives in vascular liver diseases in France, from child to adult
- Management of patients with autoimmune liver disease during COVID-19 pandemic
- Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis
- Budd-Chiari syndrome
- Pregnancy and vascular liver diseases: Vascular liver diseases: position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver
- Recent (non-cirrhotic) extrahepatic portal vein obstruction
- High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation
- Risk factors for vascular liver diseases: Vascular liver diseases: position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver
- Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group
- Sinusoidal obstruction syndrome
- Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and Noncarriers
- Management of anticoagulation in adult patients with chronic parenchymal or vascular liver disease: Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver
- Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis
- Ischemic cholangiopathy: An update
- Extrahepatic portal vein obstruction (EHPVO) in cirrhosis
- Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis
- 2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data meta‐analysis
- Genotype correlates with the natural history of severe bile salt export pump deficiency
- Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis
- Access to care in rare liver diseases: New challenges and new opportunities
Other links
Détails
- Date de publication
- 3 février 2021